POST-KALA-AZAR DERMAL LEISHMANIASIS
Clinical trials for POST-KALA-AZAR DERMAL LEISHMANIASIS explained in plain language.
Never miss a new study
Get alerted when new POST-KALA-AZAR DERMAL LEISHMANIASIS trials appear
Sign up with your email to follow new studies for POST-KALA-AZAR DERMAL LEISHMANIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old drug, new hope? ivermectin shows promise for PKDL in small trial
Disease control CompletedThis early study tested whether a common anti-parasite drug, ivermectin, could safely treat PKDL, a skin condition that can develop after kala-azar. Thirty adults in Bangladesh received either ivermectin or the standard treatment miltefosine. The goal was to see if ivermectin cou…
Matched conditions: POST-KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated May 17, 2026 16:11 UTC
-
Old drug, new hope? ivermectin shows promise for PKDL in small study
Disease control CompletedThis early study tested the safety and effectiveness of the drug ivermectin for treating post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can develop after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL took ivermectin pills for five…
Matched conditions: POST-KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated May 13, 2026 16:00 UTC